Open Payments

Yale-New Haven Hospital

Type
Teaching hospital
Where
New Haven, CT
Medicare CCN
070022
Received
$1,859,440 in 178 records, 2020 ($318,242 general, $1,541,197 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment31$318,242
2020Research payment147$1,541,197

By company

CompanyRecordsAmountYears
SEAGEN INC.70$602,4182020
Siemens Medical Solutions USA, Inc.15$317,4222020
JAZZ PHARMACEUTICALS INC.2$228,6532020
Cepheid4$197,9012020
Lilly USA, LLC2$65,0002020
Hyperfine Research, Inc.1$50,0002020
AngioDynamics, Inc.1$49,6662020
Genentech USA, Inc.1$35,0002020
Conformis, Inc.7$30,6382020
ClearPoint Neuro, Inc.1$27,5992020
Pacira Pharmaceuticals Incorporated6$27,5262020
Olympus America Inc.6$25,4452020
Cardiovascular Systems Inc.3$24,5382020
VASCULAR SOLUTIONS, INC.2$23,4272020
C. R. Bard, Inc. & Subsidiaries1$23,3302020
TransMedics, Inc.9$20,7692020
Bracco Diagnostics Inc.9$19,9202020
E.R. Squibb & Sons, L.L.C.2$19,0002020
Stryker Corporation3$17,6002020
Blue Earth Diagnostics3$12,0152020
Indivior Inc.6$6,4842020
Amgen Inc.2$5,2392020
Eisai Inc.1$5,0002020
GlaxoSmithKline, LLC.1$5,0002020
Bard Peripheral Vascular, Inc.2$4,5862020
Barco, Inc.1$4,4772020
Ipsen Biopharmaceuticals, Inc1$2,5002020
Dexcom, Inc.5$1,9522020
Vyaire Medical, Inc.1$1,9502020
VentureMed Group, Inc.1$1,8002020
GE HEALTHCARE1$1,4542020
BioFire Diagnostics, LLC1$6232020
AstraZeneca Pharmaceuticals LP6$4002020
Optinose US, Inc.1$1002020

By nature of payment

NatureRecordsAmount
Research payment147$1,541,197
Compensation for services other than consulting, including serving as faculty or as a speaker at a v3$115,000
Education2$54,666
Grant4$47,599
Gift10$47,522
Space rental or facility fees (teaching hospital only)3$42,500
Charitable Contribution9$10,954

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31Stryker Corporation$15,183GiftCash or cash equivalentNONE Device, NONE2020
2020-12-31Siemens Medical Solutions USA, Inc.$2,460Research paymentCash or cash equivalentYale New Haven Hosp Constable Neuro Clinical MR2020
2020-12-31Stryker Corporation$2,401GiftCash or cash equivalentNONE Device, NONE2020
2020-12-31Siemens Medical Solutions USA, Inc.$990Research paymentCash or cash equivalentYaleNewHavenHosp2016MRIPR1023Huber2020
2020-12-31Siemens Medical Solutions USA, Inc.$871Research paymentCash or cash equivalentYale2018MRIPR990Huber2020
2020-12-31Siemens Medical Solutions USA, Inc.$675Research paymentCash or cash equivalentYaleNewHavenHosp2019IPR925TurkBrowne2020
2020-12-31Siemens Medical Solutions USA, Inc.$580Research paymentCash or cash equivalentYale2019MRIPR990Huber2020
2020-12-31Siemens Medical Solutions USA, Inc.$127Research paymentCash or cash equivalentYaleNewHavenHosp2018MRIPR1066Constable2020
2020-12-31Stryker Corporation$15GiftCash or cash equivalentNONE Device, NONE2020
2020-12-23SEAGEN INC.$50,884Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-12-23SEAGEN INC.$9,350Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-12-23Blue Earth Diagnostics$4,005Research paymentIn-kind items and servicesAxumin Drug, Diagnostic ImagingStudy to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases2020
2020-12-23SEAGEN INC.$1,500Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-12-23SEAGEN INC.$1,293Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-12-23SEAGEN INC.$260Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2020
2020-12-17Conformis, Inc.$3,000Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-12-17Conformis, Inc.$1,500Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-12-16SEAGEN INC.$750Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-12-14SEAGEN INC.$15,965Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-12-09SEAGEN INC.$3,802Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-12-09SEAGEN INC.$325Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2020
2020-12-02Bracco Diagnostics Inc.$10,350Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-12-02SEAGEN INC.$5,240Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-12-02Conformis, Inc.$5,200Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-12-02SEAGEN INC.$2,859Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-12-02SEAGEN INC.$2,162Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-11-20Bard Peripheral Vascular, Inc.$2,860Research paymentCash or cash equivalentCOVERA Device, BD Interventional - Peripheral InterventionLutonix AV PAS CL0033012020
2020-11-18Pacira Pharmaceuticals Incorporated$12,649Research paymentCash or cash equivalentEXPAREL Drug, PAIN MANAGEMENTA MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A 2020
2020-11-18Pacira Pharmaceuticals Incorporated$1,032Research paymentCash or cash equivalentEXPAREL Drug, PAIN MANAGEMENTA MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A 2020
2020-11-17Blue Earth Diagnostics$4,005Research paymentIn-kind items and servicesAxumin Drug, Diagnostic ImagingStudy to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases2020
2020-11-05JAZZ PHARMACEUTICALS INC.$127,029Research paymentIn-kind items and servicesVYXEOS Drug, HEMATOLOGY/ONCOLOGYA STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A2020
2020-11-04Pacira Pharmaceuticals Incorporated$390Research paymentCash or cash equivalentEXPAREL Drug, PAIN MANAGEMENTA MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A 2020
2020-11-03SEAGEN INC.$39,430Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-11-03SEAGEN INC.$4,324Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-11-03SEAGEN INC.$2,406Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-11-02Blue Earth Diagnostics$4,005Research paymentIn-kind items and servicesAxumin Drug, Diagnostic ImagingStudy to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases2020
2020-10-30TransMedics, Inc.$1,690Research paymentCash or cash equivalentOrgan Care System Device, DEVICEDCD Heart2020
2020-10-29AngioDynamics, Inc.$49,666EducationIn-kind items and servicesNanoknife Device, Oncology Surgery2020
2020-10-26Lilly USA, LLC$60,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-10-20SEAGEN INC.$9,204Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-10-20Vyaire Medical, Inc.$1,950Research paymentCash or cash equivalentSuperNO2VA Device, Adult/Pediatric ventilation solutionsMulticenter Study of Saturation Targeting by Automated vs. Manual Adjustment of Inspired Oxygen in Neonates and Infants2020
2020-10-14SEAGEN INC.$2,888Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-10-09Indivior Inc.$1,594Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDLong-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults2020
2020-10-09Indivior Inc.$1,594Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDLong-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults2020
2020-10-09Amgen Inc.$239Research paymentIn-kind items and servicesOtezla Drug, InflammationI-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patient2020
2020-10-08Conformis, Inc.$2,438Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-10-07Indivior Inc.$544Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCoordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT)2020
2020-10-07Indivior Inc.$544Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCoordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT)2020
2020-10-07SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-10-07SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-10-02Pacira Pharmaceuticals Incorporated$9,100Research paymentCash or cash equivalentEXPAREL Drug, PAIN MANAGEMENTA MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A 2020
2020-10-02Pacira Pharmaceuticals Incorporated$3,965Research paymentCash or cash equivalentEXPAREL Drug, PAIN MANAGEMENTA MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A 2020
2020-09-23Siemens Medical Solutions USA, Inc.$17,825Research paymentCash or cash equivalentCorPath GRX Device, AT - Fixed interventional x-ray/angiography fluoroscopyPRECISION GRX PMS2020
2020-09-22JAZZ PHARMACEUTICALS INC.$101,623Research paymentIn-kind items and servicesVYXEOS Drug, HEMATOLOGY/ONCOLOGYCLINICAL CPX-351 INVESTIGATOR SPONSORED TRIALS2020
2020-09-18TransMedics, Inc.$1,500Research paymentCash or cash equivalentOrgan Care System Device, DEVICEDCD Heart2020
2020-09-18AstraZeneca Pharmaceuticals LP$25Charitable ContributionCash or cash equivalent2020
2020-09-17GlaxoSmithKline, LLC.$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2020
2020-09-11AstraZeneca Pharmaceuticals LP$200Charitable ContributionCash or cash equivalent2020
2020-09-11AstraZeneca Pharmaceuticals LP$50Charitable ContributionCash or cash equivalent2020
2020-09-11AstraZeneca Pharmaceuticals LP$50Charitable ContributionCash or cash equivalent2020
2020-09-09VASCULAR SOLUTIONS, INC.$15,927Research paymentCash or cash equivalentVASCULAR SOLUTIONS Device, Interventional AccessCTO Study Image Review2020
2020-09-08AstraZeneca Pharmaceuticals LP$50Charitable ContributionCash or cash equivalent2020
2020-09-04SEAGEN INC.$5,000EducationCash or cash equivalentADCETRIS Biological, Oncology2020
2020-09-04Eisai Inc.$5,000GrantCash or cash equivalentLenvima Drug, Oncology2020
2020-09-02Olympus America Inc.$14,762GiftIn-kind items and services2020
2020-09-02Olympus America Inc.$7,277GiftIn-kind items and services2020
2020-09-02Olympus America Inc.$2,119GiftIn-kind items and services2020
2020-09-02Olympus America Inc.$1,088GiftIn-kind items and services2020
2020-09-02Dexcom, Inc.$374Research paymentIn-kind items and servicesDEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGYVERY LOW CARBOHYDRATE DIETS (VLCD) IN YOUTH WITH TYPE 1 DIABETES2020
2020-09-02Olympus America Inc.$71GiftIn-kind items and services2020
2020-09-02Dexcom, Inc.$39Research paymentIn-kind items and servicesDEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGYVERY LOW CARBOHYDRATE DIETS (VLCD) IN YOUTH WITH TYPE 1 DIABETES2020
2020-08-28Cepheid$50,000Research paymentCash or cash equivalentGENEXPERT Device, MOLECULAR DIAGNOSTICS2020
2020-08-27Olympus America Inc.$125GiftIn-kind items and services2020
2020-08-24AstraZeneca Pharmaceuticals LP$25Charitable ContributionCash or cash equivalent2020
2020-08-19Amgen Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-08-18E.R. Squibb & Sons, L.L.C.$10,000GrantCash or cash equivalent2020
2020-08-13Siemens Medical Solutions USA, Inc.$870Research paymentCash or cash equivalentYale2018MRIPR990Huber2020
2020-08-13Siemens Medical Solutions USA, Inc.$580Research paymentCash or cash equivalentYale2019MRIPR990Huber2020
2020-08-05Indivior Inc.$1,103Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCoordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT)2020
2020-08-05Indivior Inc.$1,103Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCoordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT)2020
2020-08-05Pacira Pharmaceuticals Incorporated$390Research paymentCash or cash equivalentEXPAREL Drug, PAIN MANAGEMENTA MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A 2020
2020-08-04SEAGEN INC.$43,142Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-08-04SEAGEN INC.$13,879Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-08-04SEAGEN INC.$7,028Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-08-04Barco, Inc.$4,477Gift (2 payments)In-kind items and services Device, diagnostic imaging2020
2020-08-04SEAGEN INC.$260Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2020
2020-08-03Lilly USA, LLC$5,000GrantCash or cash equivalent2020
2020-07-27Genentech USA, Inc.$35,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentActivase Biological, Metabolism & Primary Care2020
2020-07-23Cardiovascular Systems Inc.$22,288Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2020
2020-07-23Conformis, Inc.$13,000Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-07-23SEAGEN INC.$3,900Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-07-23SEAGEN INC.$1,500Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-07-20Dexcom, Inc.$1,123Research paymentIn-kind items and servicesDEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGYCAPO: CONTINUOUS GLUCOSE MONITORING IN A2 GESTATIONAL DIABETES AND PREGNANCY OUTCOMES2020
2020-07-20Dexcom, Inc.$395Research paymentIn-kind items and servicesDEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGYCAPO: CONTINUOUS GLUCOSE MONITORING IN A2 GESTATIONAL DIABETES AND PREGNANCY OUTCOMES2020
2020-07-16Ipsen Biopharmaceuticals, Inc$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentONIVYDE Drug, Oncology2020
2020-07-15VentureMed Group, Inc.$1,800Research paymentCash or cash equivalentFLEX Scoring Catheter Device, VascularFLEX-AV Registry2020
2020-07-10Siemens Medical Solutions USA, Inc.$110,996Research paymentCash or cash equivalentCorPath GRX Device, AT - Fixed interventional x-ray/angiography fluoroscopyPRECISION GRX PMS2020
2020-07-09Cardiovascular Systems Inc.$1,500Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2020
2020-07-08Siemens Medical Solutions USA, Inc.$2,250Research paymentCash or cash equivalentSequoia Device, US - Ultrasound Systems3 releases of Sequoia system External Clinical Evaluation and Validation2020
2020-07-07Dexcom, Inc.$19Research paymentIn-kind items and servicesDEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGYCAPO: CONTINUOUS GLUCOSE MONITORING IN A2 GESTATIONAL DIABETES AND PREGNANCY OUTCOMES2020
2020-07-03Siemens Medical Solutions USA, Inc.$3,000Research paymentCash or cash equivalentSequoia Device, US - Ultrasound Systems3 releases of Sequoia system External Clinical Evaluation and Validation2020
2020-07-03Siemens Medical Solutions USA, Inc.$1,500Research paymentCash or cash equivalentSequoia Device, US - Ultrasound Systems3 releases of Sequoia system External Clinical Evaluation and Validation2020
2020-06-29SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-29SEAGEN INC.$750Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-25Bracco Diagnostics Inc.$1,000Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-06-22SEAGEN INC.$33,750Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-22SEAGEN INC.$18,454Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-22SEAGEN INC.$4,875Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-22SEAGEN INC.$3,900Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-22SEAGEN INC.$1,400Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-19TransMedics, Inc.$2,346Research paymentCash or cash equivalentOrgan Care System Device, DEVICEDCD Heart2020
2020-06-09SEAGEN INC.$2,308Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-06-09SEAGEN INC.$780Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2020
2020-06-08Siemens Medical Solutions USA, Inc.$174,570Research paymentCash or cash equivalentCorPath GRX Device, AT - Fixed interventional x-ray/angiography fluoroscopyPRECISION GRX PMS2020
2020-06-08SEAGEN INC.$2,600Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-08SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-06-02SEAGEN INC.$17,774Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-06-02SEAGEN INC.$499Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-06-02SEAGEN INC.$124Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-05-28Cepheid$49,300Research paymentCash or cash equivalentGENEXPERT Device, MOLECULAR DIAGNOSTICS2020
2020-05-27VASCULAR SOLUTIONS, INC.$7,500Research paymentCash or cash equivalentVASCULAR SOLUTIONS Device, Interventional AccessCTO Study Image Review2020
2020-05-19Bracco Diagnostics Inc.$1,000Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-05-13SEAGEN INC.$22,009Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-05-13SEAGEN INC.$750Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-05-07Cardiovascular Systems Inc.$750Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2020
2020-05-06SEAGEN INC.$7,028Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-05-06SEAGEN INC.$750Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-05-06SEAGEN INC.$750Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-05-06SEAGEN INC.$728Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-05-06SEAGEN INC.$124Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-05-05Hyperfine Research, Inc.$50,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesSwoop Device, Portable MRI2020
2020-05-04Optinose US, Inc.$100Charitable ContributionCash or cash equivalentXhance Drug, Otolaryngology (Ear, Nose, Throat)2020
2020-05-01TransMedics, Inc.$500Research paymentCash or cash equivalentOrgan Care System Device, DEVICEDCD Heart2020
2020-05-01TransMedics, Inc.$250Research paymentCash or cash equivalentOrgan Care System Device, DEVICEHeart Expand CAP2020
2020-05-01TransMedics, Inc.$82Research paymentCash or cash equivalentOrgan Care System Device, DEVICEDCD Heart2020
2020-04-24E.R. Squibb & Sons, L.L.C.$9,000Charitable ContributionCash or cash equivalent2020
2020-04-22SEAGEN INC.$108,688Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-04-22SEAGEN INC.$37,108Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-04-22SEAGEN INC.$520Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2020
2020-04-21Bracco Diagnostics Inc.$1,000Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-04-08Siemens Medical Solutions USA, Inc.$127Research paymentCash or cash equivalentYaleNewHavenHosp2018MRIPR1066Constable2020
2020-04-06Conformis, Inc.$3,999Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-03-25SEAGEN INC.$2,308Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-03-17Bracco Diagnostics Inc.$1,000Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-03-11SEAGEN INC.$1,010Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-03-09SEAGEN INC.$1,560Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-03-04SEAGEN INC.$1,400Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-03-04SEAGEN INC.$904Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-03-03Bracco Diagnostics Inc.$2,070Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-02-26SEAGEN INC.$904Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-02-25BioFire Diagnostics, LLC$623Research paymentCash or cash equivalentBCID2 IUO Panel Kit (RFIT-ASY-0146) Device, Clinical DiagnosticsBCID2 MEP2020
2020-02-19SEAGEN INC.$8,577Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-02-19SEAGEN INC.$1,560Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-02-18SEAGEN INC.$1,755Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-02-18Bracco Diagnostics Inc.$1,000Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-02-11Cepheid$49,300Research paymentCash or cash equivalentGENEXPERT Device, MOLECULAR DIAGNOSTICS2020
2020-02-07Bard Peripheral Vascular, Inc.$1,726Research paymentCash or cash equivalentCOVERA Device, BD Interventional - Peripheral InterventionAVeNEW BPV140052020
2020-02-03SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-01-31GE HEALTHCARE$1,454Charitable ContributionCash or cash equivalent2020
2020-01-29SEAGEN INC.$6,262Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-01-29SEAGEN INC.$372Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-01-28Bracco Diagnostics Inc.$1,000Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-01-21SEAGEN INC.$26,106Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2020
2020-01-21SEAGEN INC.$1,079Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2020
2020-01-20SEAGEN INC.$21,635Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12020
2020-01-16Conformis, Inc.$1,500Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-01-15C. R. Bard, Inc. & Subsidiaries$23,330Research paymentCash or cash equivalentArctic Sun Device, Medical SystemsINTREPID BMD11112020
2020-01-15SEAGEN INC.$11,711Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-01-14TransMedics, Inc.$8,700Research paymentCash or cash equivalentOrgan Care System Device, DEVICEDCD Heart2020
2020-01-14TransMedics, Inc.$5,200Research paymentCash or cash equivalentOrgan Care System Device, DEVICEHeart Expand CAP2020
2020-01-14TransMedics, Inc.$500Research paymentCash or cash equivalentOrgan Care System Device, DEVICEHeart Expand CAP2020
2020-01-13Cepheid$49,300Research paymentCash or cash equivalentGENEXPERT Device, MOLECULAR DIAGNOSTICS2020
2020-01-08SEAGEN INC.$11,320Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2020
2020-01-08SEAGEN INC.$3,900Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2020
2020-01-08SEAGEN INC.$1,500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2020
2020-01-08SEAGEN INC.$250Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2020
2020-01-07Bracco Diagnostics Inc.$1,500Research paymentCash or cash equivalentMultiHance Drug, Diagnostic ImagingAn Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive2020
2020-01-01ClearPoint Neuro, Inc.$27,599GrantIn-kind items and servicesClearPoint System Device, Neurology2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

South Central Connecticut Planning RegionNew Haven city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
New Haven, CT
County
South Central Connecticut Planning Region, CT
State
Connecticut
Population B01003134,349570,5983,624,508
Population, 2020 census P1134,023-3,605,944
Median age B0100231.940.241.1
Under 18 B0100121.3%19.6%20.2%
65 and over B0100111.8%18.6%18.5%
Households B1100154,773230,6731,434,007
Foreign born B0500218.0%13.7%15.7%
Median household income B19013$56,851$88,197$95,781
Median family income B19113$68,668$115,384$122,706
Per capita income B19301$36,242$49,766$55,915
Poverty rate B1700123.9%11.4%10.0%
Unemployment rate B230258.4%6.0%5.6%
Civilian labor force B2302569,528307,6071,959,490
Mean commute (minutes) B0801321.523.526.5
Bachelor's degree or higher B1500338.9%42.0%42.5%
Housing units B2500160,333248,2671,541,822
Owner-occupied B2500328.4%60.5%66.5%
Renters B2500371.6%39.5%33.5%
Median home value B25077$287,100$353,100$366,900
Median gross rent B25064$1,488$1,525$1,488
White, not Hispanic B0300230.0%58.5%61.9%
Black B0300227.6%13.0%9.8%
Hispanic or Latino B0300231.0%19.5%18.3%
Asian B030025.2%4.5%4.7%
American Indian and Alaska Native B030020.2%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.